Gilead Sciences, Inc (GILD) Fair Value & Analysis
Healthcare · US · Market cap $160B
Gilead Sciences, Inc
GILD · US
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 8 days ago
Fair value updated Jun 24, 2026 — revised from $198.51 to $146.50 (−26.2%) since Jun 23, 2026. Share price +2.9% over the past month.
Price vs Fair Value (12 months)
12‑month range $101.14 – $147.58 · fair‑value band $106.45 – $258.07 · the $125.05 price screens below the $146.50 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Gilead Sciences, Inc (GILD) currently trades at $125.05, while our model-based Fair Value estimate is $146.50 — implying the stock looks roughly 17.2% undervalued today. We read business quality at 78/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Gilead Sciences, Inc generated revenue of $29.7B at a net margin of 31.0%. Revenue grew 4.4% year over year. It earns a return on equity of 43.4%. Net debt stands at $17.0B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Gilead Sciences, Inc reported revenue of $29.4B in FY2025 versus $27.3B in FY2021, a compound +1.9%/yr. Reported net income was $8.5B in FY2025, compounding +8.1%/yr from FY2021.
Is GILD fairly valued? → Check now
Recent news
- Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX)
- Is Aurinia Pharmaceuticals Inc. (AUPH) A Good Stock To Buy Now?
- Is SELLAS Life Sciences Group, Inc. (SLS) A Good Stock To Buy Now?
- Tempus AI Stock Faces a Make-or-Break Moment After Its Recent Pullback
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,102 | $395.92 | -64% |
| JNJ JNJ | 4,128 MXN | 2,944 MXN | -29% |
| Johnson & Johnson, JNJB34 | R$78.55 | R$12.18 | -84% |
| AbbVie Inc ABBV | $230.01 | $133.86 | -42% |
| Roche Holding ROGN | 7,050 MXN | 6,743 MXN | -4% |
| Merck & Co MRK | $119.09 | $77.57 | -35% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Gilead Sciences, Inc (GILD) undervalued?
What is the fair value of GILD?
What is the quality score of GILD?
What is the revenue of Gilead Sciences, Inc (GILD)?
What is the net profit margin of GILD?
Does Gilead Sciences, Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.